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Abstract 
Few studies have documented relationships between endovascular therapy, duplex 
ultrasonography (DUS), post thrombotic syndrome (PTS), and quality of life (QOL). The Acute 
Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis 
(ATTRACT) trial randomized 692 patients with acute proximal deep vein thrombosis (DVT) to 
receive anticoagulation or anticoagulation plus pharmacomechanical catheter directed 
thrombolysis (PCDT). Compression DUS was obtained at baseline, 1-month and 12-months . 
Reflux DUS was obtained at 12-months in a subset of 126 patients.  Clinical outcomes were 
collected over 24 months . At 1-month, patients who received PCDT had less residual thrombus 
compared to Control patients evidenced by non-compressible common femoral vein (CFV) (21% 
vs. 35%, p < 0.0001), femoral vein (51% vs. 70%, p < 0.0001) and popliteal vein (61% vs. 74%, 
p < 0.0001).  At 12 months in the ultrasound substudy, valvular reflux prevalence was similar 
between groups (85% vs. 91%, p=0.35). CFV non-compressibility at 1 month was associated 
with higher rates of any PTS (61% vs. 46%, p<0.001), a higher incidence of moderate-or-severe 
PTS (30% vs. 19%, p=0.003), and worseQOL (difference 8.2 VEINES-QOL points; p=0.004) at 
24 months.  Valvular reflux at 12 months was associated with moderate-or-severe PTS at 24 
months (30% vs. 0%, p=0.01), but not with any PTS (63% versus 53%, p=0.47). In summary, 
PCDT results in less residual thrombus but does not reduce venous valvular reflux. CFV non-
compressibility at 1 month is associated with more PTS, more severe PTS, and worse QOL at 24 
months. Valvular reflux may predispose to moderate-or-severe PTS.  
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Introduction 
Post thrombotic syndrome (PTS) describes a spectrum of adverse clinical signs and symptoms 
that may develop after deep vein thrombosis (DVT). Clinical features range from minor limb 
discomfort to severe leg pain, intractable edema, irreversible skin changes, and ulceration1. 
These sequelae often result in reduced quality of life (QOL) and financial burden2, 3. 
Unfortunately, PTS is common, developing in approximately 40% of patients after a first episode 
of symptomatic DVT3, 4. Once it develops, treatment of PTS is often ineffective.  Little is known 
about how to prevent PTS once a DVT has occurred1, 5, 6.  
The natural history of DVT7, the use of duplex ultrasonography (DUS) for the diagnosis of 
DVT,8 and longitudinal post-DVT DUS characteristics have all been described9, 10. Venous 
thrombus burden diminishes in most patients following DVT and often a lumen is re-established, 
a process known as recanalization. Proximal thrombus location and greater thrombus burden are 
associated with lower recanalization rates than thrombi that are confined to the distal venous 
segments11. More rapid thrombus resolution may result in improved valvular function12, 13. In 
tandem, after DVT, the prevalence of venous reflux increases over time10.  Venous hypertension, 
vein wall inflammation and valvular reflux are considered central to the pathophysiology of 
PTS14.  
The Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed 
Thrombolysis (ATTRACT) trial (ClinicalTrials.gov NCT00790335) randomized patients with 
acute proximal DVT to receive anticoagulation or anticoagulation plus pharmacomechanical 
catheter-directed thrombolysis (PCDT)15. In ATTRACT, patient outcomes were collected over 2 
years, including the occurrence and severity of PTS and health-related QOL.  The main study 
outcomes have been reported elsewhere16-18.  We performed the current analyses to describe the 
extent of residual thrombus and valvular reflux during the 12 months after proximal DVT, to 
determine if PCDT reduced residual thrombus and valvular reflux, and to determine if residual 
thrombus and reflux in the first 12 months resulted in increased PTS and reduced QOL at 24 
months.   
  
Methods 
This was a phase 3, multicenter, randomized, open-label, assessor-blinded, controlled clinical 
trial16. The trial was approved by the institutional review boards at all participating centers, and 
all participants provided written informed consent. 
Patients with acute symptomatic proximal DVT involving the femoral, common femoral, and/or 
iliac veins (with or without other involved ipsilateral veins) were enrolled at 56 centers in the 
United States. Participants were excluded if they had symptoms for more than 14 days. Complete 
inclusion and exclusion criteria have been previously published15. 
Patients were randomly assigned in a 1:1 ratio to receive anticoagulation (control) or 
anticoagulation and PCDT (intervention). Randomization was stratified according to clinical 
center and thrombus extent (i.e. iliofemoral DVT or femoral-popliteal DVT). All patients in both 
treatment groups were provided sized-to-fit 30-40 mmHg, knee-high, graduated elastic 
compression stockings and were instructed to wear them during the daytime throughout follow-
up. Clinical follow-up was performed through 24 months post-randomization. 
A study flow diagram is presented in Figure 1. In the overall trial, 692 patients were randomized 
(355 to Control, 337 to PCDT).  One patient was found to not have qualifying proximal DVT 
immediately after randomization to PCDT and was excluded from all analyses.  Five control arm 
patients crossed over to receive PCDT during the first 7 days post-randomization, and 11 patients 
randomized to the PCDT arm did not have the procedure within 7 days, leaving 350 patients in 
the control arm and 325 patients in the PCDT arm for the per-protocol data set that was used in 
these analyses.   
Clinical outcomes 
PTS was assessed at all scheduled follow-up visits by clinician examiners who were blinded to 
treatment allocation. The occurrence of PTS was counted when, in the index leg, a patient had a 
Villalta Scale score19 of 5 or greater or a venous stasis ulcer at one or more of the 6, 12, 18 or 24 
month scheduled follow-up visits after randomization.  PTS was also counted if a patient 
underwent an unplanned endovascular procedure during follow-up due to severe, progressive 
venous-related limb symptoms (unless a Villalta score within the previous 4 weeks was lower 
than 5). The severity of PTS was assessed using the continuous Villalta score and was also 
categorized as moderate-or-severe PTS if the Villalta score was ≥10 on any occasion.  PTS 
severity was also measured by the venous clinical severity score (VCSS, score ranges from 0 to 
27)20. For both scales, higher scores indicate more severe PTS.   
In the study, venous disease-specific QOL was assessed at baseline and through 24 months post-
randomization using the patient-reported Venous Insufficiency Epidemiological and Economic 
Study Quality of Life (VEINES-QOL) measure where lower scores indicated reduced QOL21.  
Ultrasound assessments 
Prior to randomization, all patients were required to have baseline venous compression DUS that 
assessed the compressibility of the common femoral vein (CFV), femoral vein (FV), and 
popliteal vein (PV) in the index leg.  To minimize barriers to enrollment, these exams could be 
done at external facilities.  The exams had to be done within 7 days prior to randomization. 
At the 30-day post-randomization visit, all patients were required to undergo bilateral venous 
DUS to evaluate residual thrombus extent.  On these exams, the compressibility of the veins 
(CFV, FV, PV) was recorded as being either fully compressible (defined as complete apposition 
of the vein walls during application of external ultrasound probe pressure), or non-compressible 
(any other state). In addition, the extent of proximal vein thrombus was drawn on a standardized 
figure, and the residual antero-posterior diameter of the externally compressed vein was assessed 
(as a measure of residual thrombus) for the CFV at the inguinal ligament level and for the PV at 
the mid-popliteal fossa level.   
Ultrasound Substudy:   
An ultrasound substudy, with enrollment of 142 consecutive patients in 5 designated clinical 
centers, was planned as part of the original study design.  During the first 12 months of follow-
up, 13 patients were lost to follow-up, and an additional 3 patients could not have their 
ultrasound examinations included in the analysis due to data transmission errors. Hence, a total 
of 126 patients (61 PCDT Arm, 65 Control Arm) had analyzable data from the 12-month 
ultrasound exams.   
These patients underwent a detailed venous DUS of the index leg 12 months post-randomization 
with evaluation of thrombus extent and valvular reflux.  The protocol for performing DUS was 
standardized across all sites by the ultrasound core laboratory. Briefly, patients were placed in a 
supine position with the leg externally rotated at the hip and slightly flexed at the knee. Veins 
were serially visualized from the CFV to the tibio-peroneal trunk. In each segment B-mode gray 
scale imaging was performed with and without compression maneuvers, as well as color and 
spectral Doppler imaging.  
Reflux DUS was performed in the standing position 22. Using an automated cuff inflator/deflator 
with appropriately sized cuffs, the presence of reflux was assessed in the CFV, FV, profunda 
femoral vein, PV, great saphenous vein, and small saphenous vein.  While insonating the vein, 
the cuff was rapidly inflated and then rapidly deflated. Spectral Doppler waveforms as well as 
valve closure time following augmentation were recorded.  Color Doppler was used to display 
presence or absence of flow reversal within the vein. Reversed flow >0.5 seconds was considered 
positive for reflux in any given deep or superficial vein segment.  For purposes of this analysis, 
the outcome ”any reflux” was defined as the presence of reflux in any of the veins evaluated, 
while “deep reflux” was defined as the presence of reflux in the CFV, FV, profunda femoral 
vein, or PV.    
The ultrasound studies were performed in vascular laboratories that were accredited by the 
American College of Radiology or the Intersocietal Accreditation Commission – Vascular 
Testing Division.  The exams were performed by registered vascular technologists who had 
completed an ultrasound protocol training session. 
An independent core-laboratory (VasCore, the Vascular Ultrasound Core Laboratory, 
Massachusetts General Hospital, Boston, MA) credentialed the sonographers, led the ultrasound 
protocol training, provided ongoing quality oversight for the DUS exams, and adjudicated the 
ultrasound substudy 12-month compression and reflux DUS exams.  Baseline and 1-month 
compression DUS exams were not routinely reviewed by the core laboratory. 
A modified Venous Segmental Disease Score (VSDS) was calculated, as not all segments were 
available to report the original VSDS23. Obstruction was scored in the CFV (2 points), FV (1 
point), profunda femoral vein (1 point), PV (2 points), and great saphenous vein (1 point); the 
points were summed to calculate the VSDS obstruction score (total possible = 7 points).   If any 
flow was present on color and/or spectral Doppler, a score of ‘0’ was assigned to the segment. If 
there was no flow present on color and spectral Doppler, the total possible points for that 
segment were assigned.  Reflux was scored in the great saphenous vein (1 point), small 
saphenous vein (0.5 point), CFV (1 point), FV (1 point), profunda femoral vein (1 point), and PV 
(2 points); the points were summed to calculate the VSDS reflux score (total possible = 6.5 
points).  If flow reversal was present for >0.5 seconds, the full possible score was counted for 
that segment. Missing segments were scored as ‘0’, for both the obstruction and reflux scores. 
Statistical Analysis 
Because the focus of these analyses was on disease mechanisms, the analysis population 
consisted of those patients who were randomized, had DVT at enrollment, and received the 
assigned treatment. Only the index leg was included in the analysis. Descriptive statistics were 
used to summarize demographic and clinical characteristics using mean (standard deviation) or 
median (25th, 75th) for continuous variables, and frequency (percentage) for categorical variables. 
Evaluation of differences in venous sonographic outcomes (non-compressible vs compressible 
vein segments) between the control and PCDT groups used multivariable logistic regression to 
adjust for baseline compressibility status.  Differences in residual diameter between the control 
and PCDT groups were evaluated using multivariable linear regression to adjust for baseline 
compressibility status.  
The association of compressibility status of vein segments (non-compressible vs compressible) 
with late clinical and anatomical outcomes used t-tests for continuous outcomes and chi square 
tests for categorical outcomes in the overall cohort. To examine if change in CFV 
compressibility from baseline to 1 month influenced late clinical and anatomical outcomes, these 
analyses were also done on the following mutually exclusive subgroups: those who had a 
compressible CFV at baseline and those who had a non-compressible CFV at baseline, using the 
same analysis methods.   
In the ultrasound substudy, the association of compressibility status of vein segments (non-
compressible vs compressible) and presence of any or deep reflux with late clinical and 
anatomical outcomes used Wilcoxon tests for continuous outcomes and chi square tests for 
categorical outcomes.  
A two-sided P value of 0.01 or lower was considered statistically significant for all analyses to 
account for multiple testing. All analyses were conducted in SAS v9.4 (SAS Institute, Cary NC). 
   
Results 
Baseline thrombus distribution, as evident from the proportion of non-compressible venous 
segments, was similar in the PCDT and control arms (Table 1). The baseline characteristics of 
the ultrasound substudy patients were similar to the characteristics of the overall ATTRACT trial 
population (Table 1). 
Effect of PCDT Treatment Upon DUS Outcomes 
At 1 month, in the overall trial, patients in the PCDT arm had less residual thrombus as 
evidenced by: a lower proportion of non-compressible venous segments (Table 2) - CFV (21% 
PCDT vs. 35% Control, p<0.0001), FV (51% PCDT vs. 70% Control, p<0.0001), and PV (61% 
PCDT vs. 74% Control, p<0.0001); and smaller residual diameters of the CFV and PV (Table 2).   
At 12 months, in the ultrasound substudy participants, patients in the PCDT arm also had less 
residual thrombus, which reached statistical significance for the proportion with FV non-
compressibility (Table 2).  The VSDS obstruction score at 12 months did not differ between 
groups.  The distribution of completely obstructed venous segments at 12 months can be found in 
Supplemental Table S1.   
At 12 months, in the ultrasound substudy, the proportions of patients with reflux in any vein 
(85% PCDT vs. 91% Control, p=0.35) and any deep vein (83% PCDT vs. 86% Control, p=0.71) 
were similar in both groups. The anatomical distribution of refluxing segments can be found in 
Supplemental Table S2. VSDS reflux score at 12 months was similar in both groups (Table 2). 
 
Relationship of 1-month DUS findings to 12-month and 24-month outcomes 
In the overall trial, CFV non-compressibility at 1 month was associated with a higher rate of PTS 
(61% vs. 46%, p<0.001), a higher rate of moderate-or-severe PTS (30% vs. 19%, p=0.003), and 
lower QOL scores (difference 8.2 VEINES-QOL scale units, p=0.004) at 24 months (Table 3).  
In contrast, the presence of either femoral vein or popliteal vein non-compressibility at 1 month 
was not associated with a lower rate of PTS (52% vs. 44%, p=0.07), moderate-or-severe PTS 
(23% vs. 19%, p=0.23), or better QOL (p=0.26).  In the analysis that included only those patients 
with a non-compressible CFV at baseline, restoration of CFV compressibility at 1-month was 
associated with better clinical outcomes – this reached statistical significance for 24-month PTS 
(62% vs. 46%, p=.004) and QOL (difference 7.3 VEINES-QOL scale points, p=0.01), but not 
moderate-or-severe PTS (29% vs. 21%, p=0.07) (Supplemental Table S3).  In the analysis that 
included only those patients with a compressible CFV at baseline, there continued to be no 
relationship between 1-month compressibility of the femoral and popliteal veins and late clinical 
outcomes (Supplemental Table S3). 
In the ultrasound substudy, CFV non-compressibility at 1 month did not predict the presence of 
valvular reflux in the deep veins or any veins at 12 months. In contrast, FV or PV non-
compressibility at 1 month appeared to be associated with more valvular reflux at 12 months 
which reached statistical significance for any reflux (93% vs. 70%, p=0.002) and the VSDS 
Reflux Score (3.2 [1.6] vs. 1.9 [1.7], p = 0.002) but not for deep reflux (88% vs. 70%, p = 0.02). 
 
Relationship of 12-month DUS findings to 24-month clinical outcomes 
In the ultrasound substudy, compressibility of the CFV at 12 months appeared to be associated 
with favorable clinical outcomes at 24 months – these relationships approached statistical 
significance for any PTS (83% vs. 57%, p=0.02) but were less compelling for moderate-or-
severe PTS (39% vs. 22%, p=0.09) and QOL (difference 7.5 VEINES-QOL scale points, p=0.08) 
(Table 4). Compressibility of both the femoral vein and popliteal vein (compared to non-
compressibility of one or both) at 12 months was not associated with lower rates of PTS (56% 
vs. 64%, p=0.40) or with less moderate-or-severe PTS (21% vs. 27%, p=0.41) at 24 months. 
While reflux at 12 months was not associated with more any PTS (63% vs. 53%, p=0.47), it was 
associated with more moderate-or-severe PTS (30% vs. 0%, p=0.01) at 24 months. Similarly, 
there was no association of deep vein reflux with any PTS (63% vs. 58%, p=0.70), but deep vein 
reflux appeared to be associated with moderate-or-severe PTS (30% vs. 5%, p=0.02). 
Of patients who had a compressible CFV and no valvular reflux at 12 months follow-up, 6/13 
(46%) developed PTS but none (0%) developed moderate-or-severe PTS.  Of patients who had 
both a non-compressible CFV and valvular reflux at 12 months follow-up, PTS developed in 
16/20 (80%) and moderate-or-severe PTS developed in 9/20 (45%). 
 
Discussion 
In this large, randomized study of anticoagulation alone versus anticoagulation and PCDT for 
acute proximal DVT, our findings collectively suggest that: 1) the use of PCDT is associated 
with lower thrombus burden at 1-month and likely also at 12 months; 2) a thrombus-free CFV at 
1 month is associated with improved 24-month clinical outcomes, including PTS, moderate-or-
severe PTS, and QOL, but the same is not true for a thrombus-free femoral-popliteal venous 
segment; 3) in patients presenting with CFV thrombus, successful restoration of full CFV 
compressibility during the first month is associated with reduced PTS and improved QOL, and 
possibly also with reduced moderate-or-severe PTS; 4) the use of PCDT is not associated with 
less venous valvular reflux at 12 months; and 5) venous valvular reflux was not associated with 
any PTS but may have a role in progression to moderate-or-severe PTS. 
 Venous obstruction and valvular reflux contribute to venous hypertension, which has been 
considered a central component of the pathophysiology of PTS.  The “open vein hypothesis” has 
posited that preservation of late venous patency and valvular competence may prevent PTS, and 
that early thrombus removal may assist this process24-26. In a series of ultrasound studies in 
anticoagulated DVT patients, Meissner et al. found that venous segments showing delayed 
thrombus clearance were more likely to develop valvular reflux, and that reflux developed more 
often if there was DVT propagation or re-thrombosis27.   In a randomized trial evaluating 
compression therapy, Prandoni et al. found that PTS developed more frequently in proximal 
DVT patients with residual venous thrombus or popliteal valvular reflux at 6-month follow-up (n 
= 180, 47% vs. 23%, p < 0.01)28. In a prospective analysis of 93 patients who presented with 
iliofemoral DVT and underwent CDT, combining various DUS-derived measures including 
thrombus burden, venous obstruction, and venous valvular reflux was useful in PTS prediction29.  
 
However, the relationships among thrombus burden, the presence and sites of valvular reflux, 
and PTS have not been consistent24. Previous studies have demonstrated substantial rates of both 
residual thrombus and valvular reflux in patients with and without PTS. While the degree of 
initial venous occlusion may correlate with later reflux29, the effect of treatment has remained 
uncertain.  
Role of Residual Thrombus Burden and Venous Obstruction  
In ATTRACT, PCDT resulted in reduced thrombus burden at 1 month and at 12 months in the 
lower extremity proximal veins.  This finding is very similar to what was observed in a previous 
multicenter randomized trial that evaluated CDT in 189 patients with proximal DVT (the 
CaVenT study).  In that study, iliofemoral venous obstruction at 2 years (assessed by a 
combination of DUS and air plethysmography) was less prevalent in patients who underwent 
CDT (25% vs. 40%)30, to a similar degree as in ATTRACT. Furthermore, in CaVenT, 
iliofemoral venous obstruction was present in more patients who developed PTS (Villalta score ≥ 
5) as compared with those without PTS (44% vs. 23%).  
Of note, the proportion of patients with residual thrombus during follow-up was higher than one 
might expect given the extensive nature of the endovascular procedures in both studies.  It is 
unclear if this is the result of venographically occult thrombus that remained after PCDT, versus 
later development of asymptomatic recurrent thrombosis, and if additional focus on minimizing 
recurrence in the early weeks after PCDT (e.g., with improved antiplatelet and anticoagulation 
strategies, improved PCDT technique up front, or additional imaging surveillance) may prove 
beneficial in increasing the effectiveness of PCDT in PTS prevention. 
Role of Valvular Reflux 
In the Control arm of the ultrasound substudy of the ATTRACT trial, 86% of patients had deep 
venous valvular reflux after 12 months follow-up.  This finding is consistent with previous 
studies that have reported high rates of valvular reflux in patients who experienced a proximal 
DVT and were treated with either anticoagulation alone (including the randomized CaVenT 
study, 83% at 2 years)30 or with systemic thrombolysis (Laiho et al, 81%)31.    
However, in ATTRACT, PCDT did not reduce the occurrence of valvular reflux.  This finding 
differs substantially from what has been observed in previous retrospective studies32 and smaller 
randomized trials30, 33. In a randomized trial comparing pulse-spray CDT to anticoagulation alone 
for patients with iliofemoral DVT, results at 6 months were available in 35 patients and reflux 
was present in fewer patients in the pulse-spray CDT arm (11% vs. 41%)33. In the CaVenT trial 
(n=189), femoral-popliteal reflux at 2 years was present in fewer patients who underwent CDT 
(66.7% vs. 83.2%, p = 0.009)30. In that study, patients who developed PTS had more venous 
reflux at 2 years as compared with those who did not develop PTS (89.8% vs. 61.9%).  
The reasons for the differences in the effect of catheter intervention upon valvular reflux between 
ATTRACT and CaVenT are unknown.  In both studies the presence of reflux was adjudicated by 
an independent core-laboratory, but the thrombus removal method used (CDT in CaVenT, PCDT 
in ATTRACT) differed to an extent.  One possibility is that the use of mechanical thrombectomy 
devices for PCDT may promote valve injury, which could be either macroscopic or related to 
aggravation of inflammation or other biological mechanisms.  Another possibility is that a longer 
period of thrombolysis (e.g., the 48 hours in CaVenT versus the 20 hours in ATTRACT) could 
provide more complete thrombus clearance or improved inflow, contributing to restoration of 
normal vein function. Of course, it is also possible that the observed differences in valvular 
reflux between the studies are unrelated to the procedure type but stem more from differences in 
the conduct of the ultrasound assessments, differences in study size or location (Norway versus 
United States), or from the overall level of methodological rigor applied.  Unfortunately, 
ATTRACT does not provide insight into how to minimize the development of valvular reflux. 
Study Limitations 
This study is not without limitations. For budgetary reasons, it was only possible to perform 
detailed ultrasound examinations at 12 months in 142 patients, which reduced our ability to 
assess inter-relationships with the 12-month ultrasound assessments. Baseline and 1-month 
compression ultrasound assessments were not routinely centrally interpreted. Information on the 
baseline presence of reflux was not available since the study patients were only identified after 
the diagnosis of acute DVT.  Our analysis involved substantial multiple testing. Finally, while 
most of the design and outcomes were pre-specified, the sonographers did not use the defined 
VSDS venous obstruction criteria, which reduced the utility of that assessment.  
Conclusion 
In conclusion, residual thrombus and valvular reflux are present with high frequency after 
proximal DVT.  PCDT leads to reduced late residual thrombus burden but does not prevent 
venous valvular reflux from developing. While less clot burden in the CFV is associated with 
less PTS, less moderate-or-severe PTS, and better QOL, that is not the case for clot burden in the 
FV and PV. Valvular reflux may have a role in progression to moderate-or-severe PTS. Thus, to 
reduce PTS, additional study of the open vein hypothesis in the iliofemoral venous segment may 
be helpful, but new insights into alternative mechanisms (biochemical, genetic, inflammatory, 
and/or microvascular) will likely be needed to fully elucidate the pathophysiology of PTS.  
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Table 1: Baseline characteristics for overall trial participants and ultrasound substudy participants 
 
Overall Trial Ultrasound Substudy 
Total1 
(N=675) 
PCDT 
(N=325) 
Control 
(N=350) 
Total1 
(N=126) 
PCDT 
(N=61) 
Control 
(N=65) 
Age (years), median (SD) 
52.0 
(42.0, 62.0) 
52.0 
(41.0, 61.0) 
53.0 
(43.0, 62.0) 
52.0 
(41.0, 59.0) 
52.0 
(39.0, 57.0) 
52.0 
(42.0, 62.0) 
Male, n (%) 416 (62%) 197 (61%) 219 (63%) 76 (60%) 33 (54%) 43 (66%) 
White, n (%) 528 (78%) 257 (79%) 271 (77%) 107 (85%) 54 (89%) 53 (82%) 
Hispanic or Latino, n (%) 41 (6%) 15 (5%) 26 (7%) 9 (7%) 3 (5%) 6 (9%) 
BMI, median (SD) 
30.6 
(26.8, 35.7) 
30.9 
(27.5, 36.0) 
30.5 
(26.2, 35.1) 
31.4 
(27.5, 35.6) 
31.6 
(27.8, 35.5) 
31.1 
(26.4, 36.4) 
eGFR, median (SD) 
84.2 
(72.0, 98.0) 
78.0 
(70.0, 97.0) 
88.0 
(74.0, 102.0) 
93.5 
(70.0, 108.0) 
72.0 
(69.0, 97.0) 
102.0 
(92.0, 116.0) 
DVT Left Leg, n (%) 416 (62%) 203 (63%) 213 (61%) 78 (62%) 40 (66%) 38 (59%) 
Non-compressible CFV, n (%) 364/644 (57%) 179/308 (58%) 185/336 (55%) 67/122 (55%) 31/58 (53%) 36/64 (56%) 
Non-compressible FV, n (%) 598/644 (93%) 286/308 (93%) 312/336 (93%) 116/122 (95%) 53/58 (91%) 63/64 (98%) 
Non-compressible PV, n (%) 554/643 (86%) 267/308 (87%) 287/335 (86%) 108/121 (89%) 48/58 (83%) 60/63 (95%) 
1Treatment groups are per-protocol patients 
BMI=Body Mass Index, eGFR=Estimated Glomerular Filtration Rate, DVT=Deep Vein Thrombus, CFV=Common Femoral Vein, 
FV=Femoral Vein, PCDT=Pharmacomechanical Catheter-Directed Thrombolysis, PV=Popliteal Vein, SD=Standard Deviation 
  
Table 2. Effect of PCDT on Venous Sonographic Outcomes at 1 month and 12 months 
Overall 
Trial 
Status at 1 Month PCDT1 Control p-value2 
Non-compressible CFV, n (%) 63/307 (21%) 107/310 (35%) <0.0001  
CFV diameter (mm), mean (SD) 1.5 (4.3) 3.4 (7.3) 0.0002 
Non-compressible FV, n (%) 155/307 (51%) 218/312 (70%) <0.0001 
Non-compressible PV, n (%) 185/306 (61%) 231/312 (74%) <0.0001 
PV diameter (mm), mean (SD) 4.1 (4.9) 6.4 (7.2) <0.0001 
Ultrasound  
Substudy 
  
Status at 12 Months  PCDT1 Control p-value2 
Non-compressible CFV, n (%) 8/60 (13%) 15/62 (24%) 0.07 
CFV diameter (mm), mean (SD) 0.5 (1.4) 1.2 (2.4) 0.02 
Non-compressible FV, n (%) 27/61 (44%) 43/62 (69%) 0.01 
Non-compressible PV, n (%) 28/61 (46%) 45/62 (73%) 0.05 
PV diameter (mm), mean (SD) 1.9 (2.4) 3.2 (2.3) 0.05 
Obstruction score3, mean (SD) 0.08 (0.4) 0.14 (0.4) 0.49 
Reflux score3, mean (SD) 2.7 (1.7) 3.0 (1.7) 0.39 
Any reflux present, n (%) 51/60 (85%) 57/63 (91%) 0.35 
Deep reflux present, n (%) 50/60 (83%) 54/63 (86%) 0.71 
1 Treatment groups are per-protocol patients 
2 Comparisons adjusted for baseline compressibility status for CFV, PV and FV at 1 month and 
1 year 
3 Scores are derived from the modified Venous Segmental Disease Scale (VSDS) 
CFV=Common Femoral Vein, FV=Femoral Vein, PCDT=Pharmacomechanical Catheter-Directed 
Thrombolysis, PV=Popliteal Vein, SD=Standard Deviation
Table 3. Association of venous non-compressibility at 1 month with late clinical, anatomical, and physiological outcomes 
Clinical Outcome 
Status of CFV at 1 Month Status of FV and PV at 1 Month 
Non-
compressible 
Compressible p-value 
Either non-
compressible 
Both 
compressible 
p-value 
Overall 
Trial 
Any PTS, n (%) 104/170 (61%) 205/447 (46%) <0.001 241/464 (52%) 70/160 (44%) 0.07 
Moderate-or-Severe PTS, n (%) 51/170 (30%) 85/447 (19%) 0.003 108/464 (23%) 30/160 (19%) 0.23 
Villalta score at 24 months, mean (SD) 5.2 (5.8) 4.0 (4.6) 0.10 4.4 (5.1) 3.9 (4.4) 0.24 
VCSS score at 24 months, mean (SD) 2.7 (3.3) 2.1 (2.7) 0.21 2.5 (3.1) 1.7 (2.4) 0.02 
VEINES-QOL score at 24 months, mean (SD) 73.2 (24) 81.4 (20) 0.004 79.2 (21) 79.3 (24) 0.26 
        
Anatomical/Physiological Outcome 
Status of CFV at 1 Month Status of FV and PV at 1 Month 
Non-
compressible 
Compressible p-value 
Either non-
compressible 
Both 
compressible 
p-value 
Ultrasound 
Substudy 
 
Non-compressible CFV at 12 months, n (%) 22/36 (61%) 1/83 (1%) <0.001 18/93 (19%) 5/28 (18%) 0.86 
Non-compressible FV at 12 months, n (%) 23/36 (64%) 46/84 (55%) 0.35 67/94 (71%) 2/28 (7%) <0.001 
Non-compressible PV at 12 months, n (%) 18/36 (50%) 53/84 (63%) 0.18 72/94 (77%) 0/28 (0%) <0.001 
Obstruction score at 12 months, mean (SD) 0.2 (0.6) 0.1 (0.4) 0.15 0.1 (0.5) 0.04 (0.2) 0.33 
CFV diameter (mm), mean (SD) 2.8 (2.8) 0.05 (0.4) <0.001 0.9 (2.1) 0.6 (1.5) 0.57 
PV diameter (mm), mean (SD) 2.0 (2.5) 2.8 (2.4) 0.07 3.3 (2.3) 0 (0.0) <0.001 
Reflux score at 12 months, mean (SD) 3.0 (1.8) 2.8 (1.7) 0.57 3.2 (1.6) 1.9 (1.7) 0.002 
Any reflux present at 12 months, n (%) 31/36 (86%) 74/84 (88%) 0.76 88/95 (93%) 19/27 (70%) 0.002 
Deep reflux present at 12 months, n (%) 30/36 (83%) 71/84 (85%) 0.87 84/95 (88%) 19/27 (70%) 0.02 
CFV=Common Femoral Vein, FV=Femoral Vein, PTS=Post-thrombotic syndrome, PV=Popliteal Vein, SD=Standard Deviation, 
VCSS=Venous Clinical Severity Score, VEINES-QOL=Venous Insufficiency Epidemiological and Economic Study Quality of Life 
Table 4. Association of 12-month venous sonographic findings with 24-month clinical outcomes in Ultrasound Sub-study 
Clinical Outcome 
Status of CFV at 12 Months Status of FV and PV at 12 Months 
Non-
compressible 
Compressible p-value
Either non-
compressible 
Both 
compressible 
p-value
Any PTS, n (%) 19/23 (83%) 56/99 (57%) 0.02 54/84 (64%) 22/39 (56%) 0.40 
Moderate-or-Severe PTS, n (%) 9/23 (39%) 22/99 (22%) 0.09 23/84 (27%) 8/39 (21%) 0.41 
Villalta score at 24 months, mean (SD) 6.4 (5.5) 4.2 (4.3) 0.06 4.8 (4.8) 4.1 (4.3) 0.45 
VCSS score at 24 months, mean (SD) 2.8 (2.7) 1.9 (2.5) 0.11 2.4 (2.7) 1.5 (2.2) 0.05 
VEINES-QOL score at 24 months, mean (SD) 72.2 (19) 79.7 (22) 0.08 77.9 (21) 78.8 (24) 0.37 
Clinical Outcome 
Any Reflux at 12 Months Deep Reflux at 12 Months 
Yes No p-value Yes No p-value
Any PTS, n (%) 68/108 (63%) 8/15 (53%) 0.47 65/104 (63%) 11/19 (58%) 0.70 
Moderate-or-Severe PTS, n (%) 32/108 (30%) 0/15 (0%) 0.01 31/104 (30%) 1/19 (5%) 0.02 
Villalta score at 24 months, mean (SD) 4.9 (4.8) 2.7 (2.7) 0.10 4.9 (4.8) 3.2 (3.1) 0.23 
VCSS score at 24 months, mean (SD) 2.3 (2.6) 1.3 (1.9) 0.12 2.3 (2.7) 1.4 (1.8) 0.24 
VEINES-QOL score at 24 months, mean (SD) 77.3 (22) 82.0 (20) 0.39 77.5 (22) 79.9 (22) 0.53 
CFV=Common Femoral Vein, FV=Femoral Vein, PTS=Post-thrombotic syndrome, PV=Popliteal Vein, SD=Standard Deviation, 
VCSS=Venous Clinical Severity score, VEINES-QOL=Venous Insufficiency Epidemiological and Economic Study Quality of Life 
Figure 1: Consort diagram 
Figure 1 Legend:  Study flow diagram for the overall ATTRACT Trial and the ultrasound substudy 
Supplemental Table S1 
Percentage of Patients in Ultrasound Substudy with Obstruction* 
in each evaluated venous segment at 12 months 
 
Venous Segment 
Total 
(N=123) 
PCDT 
(N=60) 
Control 
(N=63) 
CFV Obstructed, n (%) 1 (0.8%) 0 (0.0%) 1 (1.6%) 
FV Obstructed, n (%) 8 (6.5%) 3 (5.0%) 5 (7.9%) 
Profunda FV Obstructed, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Popliteal Obstructed, n (%) 2 (1.6%) 1 (1.7%) 1 (1.6%) 
GSV Obstructed, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Iliac Obstructed, n (%) 1 (0.8%) 0 (0.0%) 1 (1.6%) 
 
* Complete absence of flow on color and spectral Doppler  
CFV=Common Femoral Vein, FV=Femoral Vein, GSV=Great Saphenous Vein, 
SSV=Small Saphenous Vein 
 
Supplemental Table S2 
Percentage of Patients in Ultrasound Substudy with Reflux 
in each evaluated venous segment at 12 months 
 
Venous Segment Total PCDT Control 
CFV Reflux, n (%) 46/123 (37%) 23/60 (38.3%) 23/63 (36.5%) 
FV Reflux, n (%) 74/122 (61%) 33/60 (55.0%) 41/62 (66.1%) 
Profunda FV Reflux, n (%) 21/123 (17%)  7/60 (11.7%) 14/63 (22.2%) 
Popliteal Reflux, n (%) 84/123 (68%) 38/60 (63.3%) 46/63 (73.0%) 
GSV Reflux, n (%) 29/123 (24%) 16/60 (26.7%) 13/63 (20.6%) 
SSV Reflux, n (%) 30/123 (24%) 14/60 (23.3%) 16/63 (25.4%) 
 
 
 
 
 
 
Supplemental Table S3 
Association of restoration of venous non-compressibility at 1 month with late outcomes 
Clinical Outcome 
Status of CFV at 1 Month for Patients with 
Non-Compressible CFV at Baseline 
Status of FV and PV at 1 Month for Patients 
with Compressible CFV at Baseline 
Still Non-
compressible 
Became 
Compressible 
p-value 
Either non-
compressible 
Both now 
compressible 
p-
value 
Overall 
Trial 
Any PTS, n (%) 91/147 (62%) 82/179 (46%) 0.004 99/220 (45%) 22/46 (48%) 0.73 
Moderate-Severe PTS, n (%) 43/147 (29%) 37/179 (21%) 0.07 42/220 (19%) 9/46 (20%) 0.94 
Villalta score at 24 months, mean (SD) 5.2 (6.0) 4.3 (4.8) 0.18 3.8 (4.5) 4.3 (4.5) 0.55 
VCSS score at 24 months, mean (SD) 2.7 (3.4) 2.3 (3.0) 0.32 2.1 (2.7) 1.6 (1.7) 0.26 
VEINES-QOL score at 24 months, mean (SD) 73.0 (24) 80.3 (21) 0.01 82.4 (19) 75.7 (25) 0.09 
 
CFV=Common Femoral Vein, FV=Femoral Vein, PV=Popliteal Vein, SD=Standard Deviation, 
VCSS=Venous Clinical Severity Score, VEINES-QOL=Venous Insufficiency Epidemiological and 
Economic Study Quality of Life, PTS=post-thrombotic syndrome 
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Bulgaru, Renuka Dulala, James Burch, Dinesh Kapur, Jie Yang 
Florida Hospital: Mark Ranson – site PI, Alan Wladis, David Varnagy, Tarek Mekhail, 
Robert Winter, Manuel Perez-Izquierdo 
Forsyth Medical Center: Stephen Motew – site PI, Robin Royd-Kranis, Raymond 
Workman, Scott Kribbs, Gerald Hogsette, Phillip Moore, Bradley Thomason, William 
Means, Richard Bonsall, John Stewart, Daniel Golwya 
Gundersen Clinic, Ltd.: Ezana Azene – site PI, Wayne Bottner, William Bishop, Dave 
Clayton, Lincoln Gundersen, Jody Riherd, Irina Shakhnovich, Kurt Ziegelbein 
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Georgetown University: Thomas Chang – site PI, Karun Sharma – previous site PI, 
Sandra Allison, Fil Banovac, Emil Cohen, Brendan Furlong, Craig Kessler, Mike 
McCullough, Jim Spies 
Henry Ford Health System: Judith Lin – site PI, Scott Kaatz, Todd Getzen, Joseph 
Miller, Scott Schwartz, Loay Kabbani, David McVinnie 
Holy Name Medical Center: John Rundback – site PI, Joseph Manno, Richard 
Schwab, Randolph Cole, Kevin Herman, David Singh, Ravit Barkama, Amish Patel 
Jobst Vascular Center: Anthony Comerota – site PI, John Pigott, Andrew Seiwert, 
Ralph Whalen, Todd Russell, Zakaria Assi, Sahira Kazanjian, Jonathan Yobbagy, Brian 
Kaminski, Allan Kaufman, Garett Begeman, Robert DiSalle, Subash Thakur 
Maine Medical Center: Paul Kim – site PI, Marc Jacquet, Thomas Dykes, Joseph 
Gerding, Christopher Baker, Mark Debiasto, Derek Mittleider, George Higgins III, 
Steven Amberson, Roger Pezzuti, Thomas Gallagher PA-C 
Massachusetts General Hospital: Robert Schainfeld – site PI, Stephan Wicky – 
previous site PI, Sanjeeva Kalva, Gregory Walker, Gloria Salazar, Benjamin Pomerantz, 
Virenda Patel, Christopher Kabrhel, Shams Iqbal, Suvranu Gangull, Rahmi Oklu, Scott 
Brannan 
Mayo Clinic: Sanjay Misra – site PI, Haraldur Bjarnason – previous site PI, Aneel 
Ashrani, Michael Caccavale, Chad Fleming, Jeremy Friese, John Heit, Manju Kalra, 
Thanila Macedo, Robert McBane, Michael McKusick, Andrew Stockland, David 
Woodrum, Waldemar Wysokinski 
Mease Countyside Hospital: Adarsh Verma – site PI, Andrew Davis – previous site PI, 
Jerry Chung, David Nicker, Brian Anderson, Robert Stein, Michael Weiss 
Medical College of Wisconsin/Froedtert Hospital & Clinics: Parag Patel – site PI, 
William Rilling, Sean Tutton, Robert Hieb, Eric Hohenwalter, M. Riccardo Colella, 
James Gosset, Sarah White, Brian Lewis, Kellie Brown, Peter Rossi, Gary Seabrook 
Medical University of South Carolina: Marcelo Guimaraes – site PI, J. Bayne Selby, 
William McGary, Christopher Hannegan, Jacob Robison, Thomas Brothers, Bruce Elliott, 
Nitin Garg, M. Bret Anderson, Renan Uflacker, Claudio Schonholz, Laurence Raney, 
Charles Greenberg 
Oregon Health & Science University: John Kaufman – site PI, Frederick Keller, 
Kenneth Kolbeck, Gregory Landry, Erica Mitchell, Robert Barton, Thomas DeLoughery, 
Norman Kalbfleisch, Renee Minjarez, Paul Lakin, Timothy Liem, Gregory Moneta, 
Khashayar Farsad, Ross Fleischman, Loren French 
Pepin Heart Hospital and Dr. Kiran C. Patel Research Institute: Vasco Marques – 
site PI, Yasir Al-Hassani, Asad Sawar, Frank Taylor 
Phoenix Heart & Cardiovascular: Rajul Patel – site PI, Rahul Malhotra – previous site 
PI, Stanley Kim, Farah Hashemi, Joseph Boyle, Nilesh Patel, Marvin Padnick , Melissa 
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Gurley, Fred Cucher, Ronald Sterrenberg, G. Reshmaal Deepthi, Gomes 
Cumaranatunge 
Riverside Methodist Hospital: Sumit Bhatla – site PI, Darick Jacobs, Eric Dolen, 
Pablo Gamboa, L. Mark Dean, Thomas Davis, John Lippert, Sanjeev Khanna, Brian 
Schirf, Jeffrey Silber, Donald Wood, J. Kevin McGraw, Lucy LaPerna, Paul Willette 
Rhode Island Hospital: Timothy Murphy – site PI, Joselyn Cerezo, Rajoo Dhangana, 
Sun Ho Ahn, Gregory Dubel, Richard Haas, Bryan Jay, Ethan Prince, Gregory Soares, 
James Klinger, Robert Lambiase, Gregory Jay, Robert Tubbs, Michael Beland, Chris 
Hampson, Ryan O’Hara, Chad Thompson, Michael Beland, Aaron Frodsham, Fenwick 
Gardiner, Abdel Jaffan, Lawrence Keating, Abdul Zafar 
Providence Sacred Heart Medical Center & Children’s Hospital: Radica Alicic – site 
PI, Rodney Raabe – previous site PI, Jayson Brower, David McClellan, Thomas Pellow, 
Christopher Zylak, Joseph Davis, M. Kathleen Reilly, Kenneth Symington, Camerson 
Seibold, Ryan Nachreiner, Daniel Murray, Stephen Murray, Sandeep Saha, Gregory 
Luna 
Southern Illinois University: Kim Hodgson – site PI, Robert McLafferty – previous site 
PI, Douglas Hood, Colleen Moore, David Griffen 
St. Elizabeth Healthcare Edgewood (KY): Darren Hurst – site PI, David Lubbers, 
Daniel Kim, Brent Warren, Jeremy Engel, D. P. Suresh 
St. Elizabeth Regional Medical Center (NE): Eric VanderWoude – site co-PI, Rahul 
Razdan – site co-PI, Mark Hutchins, Terry Rounsborg, Madhu Midathada, Daniel 
Moravec, Joni Tilford, Daniel Kim, Joni Beckman PA 
St. Joseph Hospital: Mahmood Razavi – site PI, Kurt Openshaw, D. Preston Flanigan, 
Christopher Loh, Howard Dorne, Michael Chan 
St. Luke’s Hospital and Health Network: Jamie Thomas – site PI, Justin Psaila, 
Michael Ringold, Jay Fisher, Any Lipcomb, Timothy Oskin 
St. Luke’s Hospital: Brandt Wible – site PI, Brendan Coleman, David Elliott, Gary 
Gaddis, C. Doug Cochran 
St. Vincent Medical Group: Kannan Natarajan – site PI, Stewart Bick, Jeffrey Cooke, 
Ann Hedderman, Anne Greist, Lorrie Miller, Brandon Martinez, Vincent Flanders, Mark 
Underhill 
Stanford University Medical Center: Lawrence Hofmann – site PI, Daniel Sze, William 
Kuo, John Louie, Gloria Hwang, David Hovsepian, Nishita Kothary, Caroline Berube, 
Donald Schreiber, Brooke Jeffrey 
Staten Island University Hospital: Jonathan Schor – site PI, Jonathan Deitch, 
Kuldeep Singh, Barry Hahn, Brahim Ardolic, Shilip Gupta 
Temple University Hospital: Riyaz Bashir – site PI, Angara Koneti Rao, Manish Garg, 
Pravin Patil, Chad Zack, Gary Cohen, Frank Schmieder, Valdimir Lakhter 
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The Reading Hospital: David Sacks – site PI, Robert Guay, Mark Scott, Karekin 
Cunningham, Adam Sigal, Terrence Cescon, Nick Leasure, Thiruvenkatasamy 
Dhurairaj 
TriHealth/Good Samaritan Hospital: Patrick Muck – site PI, Kurt Knochel, Joann Lohr, 
Jose Barreau, Matthew Recht, Jayapandia Bhaskaran, Ranga Brahmamdam, David 
Draper, Apurva Mehta, James Maher 
University of Iowa: Melhem Sharafuddin – site PI, Steven Lentz, Andrew Nugent, 
William Sharp, Timothy Kresowik, Rachel Nicholson, Shiliang Sun, Fadi Youness, Luigi 
Pascarella 
University of Illinois- Chicago: Charles Ray – site PI, Martha-Gracia Knuttinen – 
previous site PI, James Bui, Ron Gaba, Valerie Dobiesz, Ejaz Shamim, Sangeetha 
Nimmagadda, David Peace, Aarti Zain, Alison Palumto 
University of Maryland: Ziv Haskal – site PI, Jon Mark Hirshon, Howard Richard, 
Avelino Verceles, Jade Wong-You-Chong, Bertrand Othee, Rahul Patel, Bogdan Iliescu 
University of Michigan Hospitals and Health Centers: David Williams – site PI, 
Joseph Gemmete, Venkataramu Krishnamurthy, Wojciech Cwikiel, Kyung Cho, James 
Schields, Ranjith Vellody, Paula Novelli, Narasimham Dasika, Thomas Wakefield, John 
Rectenwald, Peter Henke, Jeffrey Desmond, James Froehlich, Minhajuddin Khaja 
University of Minnesota: David Hunter – site PI, Jafar Golzarian, Erik Cressman, 
Yvonne Dotta, Nate Schmiechen 
University of New Mexico: John Marek – site PI, David Garcia, Isaac Tawil, Mark 
Langsfeld 
University of North Carolina: Stephan Moll – site PI, Matthew Mauro, Joseph Stavas, 
Charles Burke, Robert Dixon, Hyeon Yu, Blair Keagy, Kyuny Kim, Raj Kasthuri, Nigel 
Key 
University of Pittsburgh: Rabih Chaer – site PI, Michael Makaroun, Robert Rhee, Jae-
Sung Cho, Donald Baril, Luke Marone, Margaret Hseih, Kristian Feterik, Roy Smith, 
Geetha Jeyabalan, Jennifer Rogers 
University of Utah Medical Center: Russel Vinik – site PI, Dan Kinikini, Larry Kraiss, 
Michelle Mueller, Robert Pendleton, Matthew Rondina, Mark Sarfati, Nathan Wanner, 
Stacy Johnson, Christy Hopkins, Daniel Ihnat 
University of Virginia Health System: John Angle – site PI, Alan Matsumoto, Nancy 
Harthun, Ulku Turba, Wael Saad, Brian Uthlaut, Srikant Nannapaneni, David Ling, 
Saher Sabri, John Kern, B. Gail Macik, George Hoke, Auh Wahn Park, James Stone, 
Benjamin Sneed, Scott Syverud, Kelly Davidson, Aditya Sharma, Ziv Haskal, Luke 
Wilkins 
Utah Valley Reginal Medical Center: Carl Black – site PI, Mark Asay, Daniel Hatch, 
Robert Smilanich, Craig Patten, S. Douglas Brown, Ryan Nielsen, William Alward, John 
Collins, Matthew Nokes 
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Wake Forest Baptist Health: Randolph Geary – site PI, Matthew Edwards, Christopher 
Godshall, Pavel Levy 
Weill Cornell Medical College: Ronald Winokur – site PI, Akhilesh Sista – previous 
site PI, David Madoff, Kyungmouk Lee, Bradley Pua, Maria DeSancho, Raffaele Milizia, 
Jing Gao 
Western Penn Allegheny Health System: Swapna Goday – site PI, Margaret 
Kennedy – previous site PI, Robert Kaplan, Thomas Campbell, Gordon McLean, Jamie 
Hartman, Elmer Nahum, Sanualah Khalid 
Washington University in St. Louis: Suresh Vedantham – site PI, Larry Lewis, Nael 
Saad, Mark Thoelke, Robert Pallow, Seth Klein, Gregorio Sicard 
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